Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. (2022)
Attributed to:
MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches (MASTERPLANS)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/lupus-2021-000584
PubMed Identifier: 35640982
Publication URI: http://europepmc.org/abstract/MED/35640982
Type: Journal Article/Review
Volume: 9
Parent Publication: Lupus science & medicine
Issue: 1
ISSN: 2053-8790